# The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS

> **NCT04391361** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Respiratory Function
- Scopolamine

## Interventions

- **DRUG:** Scopolamine, atropine, edaravone and dexmedetomidine
- **DRUG:** Edaravone

## Key facts

- **NCT ID:** NCT04391361
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04391361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04391361, "The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04391361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*